Interesting....so if ResAppDx get CE/TGA approved for all respiratory diseases due to the excellent AUS double blind and independent study that exceeded management expectation following the ISO protocol framework, it means that the FDA could possibly approve it for pneumonia and bronchitis even though they were only 60%......???
Ann: ResApp Clears Major Milestone for CE and TGA with ISO 13485, page-39
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)